WIRE — New Delhi [India], August 6 (ANI): Biocon expects to deliver a stronger performance as FY27 progresses, with growth momentum set to accelerate during the year and a meaningful pickup in the second half for its biosimilars business, according to the company's management commentary in its Q1 FY27 investor presentation released on Thursday. The company also said it does not expect any material increase in competitive inte
"We aggregate wires to encourage regional discovery, sending readers directly back to the original source to explore full coverage."
This is a normalized overview of the breaking feed event. The complete, official release detailing all points, background context, and statements remains hosted by the original publisher.